NASDAQ:MEDP Medpace (MEDP) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free MEDP Stock Alerts $407.15 +30.89 (+8.21%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$355.79▼$414.6150-Day Range$372.00▼$413.3152-Week Range$187.03▼$419.42Volume808,112 shsAverage Volume249,150 shsMarket Capitalization$12.61 billionP/E Ratio45.85Dividend YieldN/APrice Target$382.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Medpace alerts: Email Address Medpace MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside2.8% Downside$395.60 Price TargetShort InterestHealthy3.82% of Float Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment0.64Based on 22 Articles This WeekInsider TradingSelling Shares$76.65 M Sold Last QuarterProj. Earnings Growth20.89%From $10.53 to $12.73 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.59 out of 5 starsMedical Sector81st out of 909 stocksCommercial Physical Research Industry3rd out of 12 stocks 1.4 Analyst's Opinion Consensus RatingMedpace has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMedpace has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.82% of the float of Medpace has been sold short.Short Interest Ratio / Days to CoverMedpace has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Medpace has recently decreased by 1.76%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMedpace does not currently pay a dividend.Dividend GrowthMedpace does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMedpace has received a 72.85% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Medical devices engineering", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Medpace is -0.62. Previous Next 3.1 News and Social Media Coverage News SentimentMedpace has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Medpace this week, compared to 6 articles on an average week.Search Interest15 people have searched for MEDP on MarketBeat in the last 30 days. This is an increase of 88% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is a decrease of -64% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medpace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $76,651,647.00 in company stock.Percentage Held by Insiders20.30% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Medpace are expected to grow by 20.89% in the coming year, from $10.53 to $12.73 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medpace is 45.85, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Medpace is 45.85, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 249.54.Price to Earnings Growth RatioMedpace has a PEG Ratio of 1.97. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioMedpace has a P/B Ratio of 22.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Medpace Stock (NASDAQ:MEDP)Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.Read More MEDP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEDP Stock News HeadlinesApril 23, 2024 | markets.businessinsider.comDecoding 5 Analyst Evaluations For Medpace HldgsApril 23, 2024 | seekingalpha.comMedpace Holdings, Inc. 2024 Q1 - Results - Earnings Call PresentationApril 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 22, 2024 | investorplace.comMEDP Stock Earnings: Medpace Hldgs Beats EPS, Misses Revenue for Q1 2024April 22, 2024 | sfgate.comMedpace: Q1 Earnings SnapshotApril 22, 2024 | msn.comMedpace GAAP EPS of $3.20 beats by $0.73, revenue of $511M misses by $1MApril 22, 2024 | finance.yahoo.comMedpace Holdings Inc (MEDP) Surpasses Analyst Revenue and Earnings Projections in Q1 2024April 22, 2024 | businesswire.comMedpace Holdings, Inc. Reports First Quarter 2024 ResultsApril 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 19, 2024 | msn.comMedpace Q1 2024 Earnings PreviewApril 17, 2024 | msn.comAn iconic bar returns (and the 3 best things I ate last week)April 17, 2024 | markets.businessinsider.comMedpace Holdings Inc hosts conference call for investorsApril 15, 2024 | americanbankingnews.comFinancial Survey: Medpace (NASDAQ:MEDP) and OneMedNet (NASDAQ:ONMD)April 15, 2024 | americanbankingnews.comMedpace (MEDP) to Release Quarterly Earnings on MondayApril 11, 2024 | benzinga.comIf You Invested $1000 In This Stock 5 Years Ago, You Would Have $6,800 TodayApril 8, 2024 | finance.yahoo.comEstimating The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)April 5, 2024 | finance.yahoo.comMedpace Holdings (MEDP) is Maintaining a Healthy Margin ProfileMarch 28, 2024 | businesswire.comMedpace Holdings, Inc. to Report First Quarter 2024 Financial Results on April 22, 2024March 28, 2024 | businesswire.comMedpace Holdings, Inc. to Report First Quarter 2024 Financial Results on April 22, 2024March 28, 2024 | msn.comAlara is Madisonville's newest American restaurant, latest from popular restaurant groupMarch 27, 2024 | msn.comNew restaurant opens in Cincinnati's Madisonville neighborhoodMarch 25, 2024 | bizjournals.comLooking Glass Hospitality announces menu, hours for new $6.5M upscale restaurant, AlaraMarch 22, 2024 | finance.yahoo.comShould You Invest in Medpace (MEDP)?March 22, 2024 | finance.yahoo.comInvestors in Medpace Holdings (NASDAQ:MEDP) have seen enviable returns of 609% over the past five yearsMarch 19, 2024 | finance.yahoo.comDoes Medpace Holdings (MEDP) Have The Potential to Maintain Strong Growth?March 18, 2024 | insidermonkey.comInsiders Are Selling These 5 Stocks in 2024March 17, 2024 | bizjournals.comConvergence of factors powers the innovative ecosystem’s competitive advantage in OhioSee More Headlines Receive MEDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/22/2024Today4/23/2024Next Earnings (Estimated)7/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolNASDAQ:MEDP CUSIPN/A CIK1668397 Webwww.medpace.com Phone(513) 579-9911Fax513-579-0444Employees5,900Year FoundedN/APrice Target and Rating Average Stock Price Target$395.60 High Stock Price Target$452.00 Low Stock Price Target$273.00 Potential Upside/Downside-6.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$8.88 Trailing P/E Ratio45.85 Forward P/E Ratio38.67 P/E Growth1.97Net Income$282.81 million Net Margins15.00% Pretax Margin17.80% Return on Equity63.98% Return on Assets19.02% Debt Debt-to-Equity RatioN/A Current Ratio0.64 Quick Ratio0.64 Sales & Book Value Annual Sales$1.89 billion Price / Sales6.69 Cash Flow$11.03 per share Price / Cash Flow36.92 Book Value$18.22 per share Price / Book22.35Miscellaneous Outstanding Shares30,980,000Free Float24,693,000Market Cap$12.61 billion OptionableOptionable Beta1.38 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. August James Troendle M.D. (Age 68)Chairman & CEO Comp: $1.68MMr. Jesse J. Geiger BBA (Age 50)CPA, President Comp: $876.92kMr. Kevin M. Brady (Age 49)CFO & Treasurer Comp: $636.58kMs. Susan E. Burwig BSN (Age 61)MA, Executive Vice President of Operations Comp: $1MMr. Stephen P. Ewald J.D. (Age 55)Chief Compliance Officer, General Counsel & Corporate Secretary Comp: $826.17kBrandon EbkenChief Information OfficerMs. Lauren MorrisAssociate Director of Investors RelationsMr. Todd MeyersVice President of Business Development & MarketingJohn T. Wynne MBASenior Vice President of Commercial Operations & Clinical Pharmacology UnitMr. Reinilde Heyrman M.D. (Age 63)Chief Medical Officer of Medical Department More ExecutivesKey CompetitorsIncyteNASDAQ:INCYCharles River Laboratories InternationalNYSE:CRLPRA Health SciencesNASDAQ:PRAHExelixisNASDAQ:EXELLaboratory Co. of AmericaNYSE:LHView All CompetitorsInsiders & InstitutionsLouisiana State Employees Retirement SystemBought 200 shares on 4/23/2024Ownership: 0.022%Fifth Third BancorpSold 263 shares on 4/23/2024Ownership: 0.008%Nations Financial Group Inc. IA ADVBought 184 shares on 4/23/2024Ownership: 0.006%Duncker Streett & Co. Inc.Bought 321 shares on 4/23/2024Ownership: 0.001%Arcadia Investment Management Corp MIBought 29 shares on 4/23/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions MEDP Stock Analysis - Frequently Asked Questions Should I buy or sell Medpace stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MEDP shares. View MEDP analyst ratings or view top-rated stocks. What is Medpace's stock price target for 2024? 5 analysts have issued 12-month price targets for Medpace's shares. Their MEDP share price targets range from $273.00 to $452.00. On average, they anticipate the company's share price to reach $395.60 in the next twelve months. This suggests that the stock has a possible downside of 2.8%. View analysts price targets for MEDP or view top-rated stocks among Wall Street analysts. How have MEDP shares performed in 2024? Medpace's stock was trading at $306.53 at the beginning of the year. Since then, MEDP shares have increased by 32.8% and is now trading at $407.15. View the best growth stocks for 2024 here. When is Medpace's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 22nd 2024. View our MEDP earnings forecast. How were Medpace's earnings last quarter? Medpace Holdings, Inc. (NASDAQ:MEDP) announced its earnings results on Monday, April, 22nd. The company reported $3.20 earnings per share for the quarter, beating the consensus estimate of $2.45 by $0.75. The company earned $511 million during the quarter, compared to analyst estimates of $512.39 million. Medpace had a trailing twelve-month return on equity of 63.98% and a net margin of 15.00%. The company's revenue was up 17.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.27 EPS. What ETFs hold Medpace's stock? ETFs with the largest weight of Medpace (NASDAQ:MEDP) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Congress SMid Growth ETF (CSMD), Argent Mid Cap ETF (AMID), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Invesco S&P MidCap Quality ETF (XMHQ), First Trust Health Care AlphaDEX Fund (FXH) and Alpha Architect U.S. Quantitative Momentum ETF (QMOM). What guidance has Medpace issued on next quarter's earnings? Medpace updated its FY 2024 earnings guidance on Monday, April, 22nd. The company provided earnings per share (EPS) guidance of 10.790-11.470 for the period, compared to the consensus EPS estimate of 10.610. The company issued revenue guidance of $2.2 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion. What is August Troendle's approval rating as Medpace's CEO? 268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Medpace own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG). When did Medpace IPO? Medpace (MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers. Who are Medpace's major shareholders? Medpace's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (3.15%), Los Angeles Capital Management LLC (0.85%), Congress Asset Management Co. MA (0.50%), Rice Hall James & Associates LLC (0.39%), Raymond James & Associates (0.16%) and Westwind Capital (0.14%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Robert O Kraft, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc. View institutional ownership trends. How do I buy shares of Medpace? Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MEDP) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryThe Next Nvidia?InvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medpace Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.